A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs RG 125 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2016.
- 27 Oct 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2016.